2-heteroarylamino-pyrimidine derivatives as kinase inhibitors

US8288540B2 · kind B2 · utility

Assignee

• IRM Inc. · BM

Inventors

• Donatella Chianelli · San Diego, US
• Valentina Molteni · San Diego, US
• Xiaolin Li · San Diego, US
• Xiaodong Liu · Beijing, CN
• Juliet Nabakka · San Diego, US
• Jon Loren · San Diego, US

Key dates

• Filing date: Aug 18, 2008
• Grant date: Oct 16, 2012
• Expiry date: Mar 25, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D409/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compounds of Formula (I) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, Fms, KDR, c-raf or b-raf kinases.